Penpulimab can effectively reduce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), enhancing anti-tumor efficacy while optimizing treatment safety and reducing autoimmune-related adverse reactions.
Authentic
Guarantee
Fast Delivery
Privacy Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



